Zimbabwe has rejected a substantial US health deal valued at $367m (£272m) over five years due to Washington's demand for confidential data.
The decision was revealed after a government memo from December was leaked, revealing that Head of State Emmerson Mnangagwa felt the deal was "lopsided".
A government representative has since stated that the US was requesting health data for research and commercial purposes but was unwilling to guarantee the benefits from any future vaccines.
"We will now turn to the difficult and regrettable task of scaling back our health assistance in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had furnished over $1.9bn in health funding to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has appealed for continued negotiations to secure a deal suitable to both sides so the country's vital HIV treatment initiative can continue.
Wider Implications
This rejection follows a similar case in Kenya, where a court blocked a related deal with the US after legal challenges were raised about the security of Kenyans' medical information.
Since resuming the presidency recently, US President Donald Trump has reduced foreign aid and closed the US Agency for International Development (USAID).
The agency had managed assistance for the US government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government deals to boost transparency and responsibility.
As per reports, Sixteen African countries have so far agreed to these new agreements, representing over $18.3bn in new funding.
Details of the Rejected Agreement
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"We believe this collaboration could have provided immense advantages for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana argued the arrangement was "asymmetrical".
"Zimbabwe was being asked to provide its genetic material and health information for a long time, without any equivalent guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," he stated.
"Put simply, our country would provide the raw materials for medical research with no certainty that the end products would be accessible to our people if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further said that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were undermining systems previously set up via the international organization.
The spokesperson cited its Pathogen Access and Benefit Sharing scheme designed to deal with future pandemics.
"This framework is intended to ensure that when a country contributes its samples, the resulting advantages – such as vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
These objections over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome continued discussions with our US partners on how future co-operation might be arranged in a way that respects the sovereignty and interests of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but urged that talks must proceed since much of the nation's Aids initiatives depended on foreign aid.
"Where technical issues arise, such as those involving data governance or agreement terms, these can frequently be resolved through technical clarification and negotiated safeguards," it commented.
The halted deal underscores the continuing debate between accepting crucial foreign assistance and protecting a country's data in an ever more interconnected world.